Caris Life Sciences Study Identifies Clinically Significant Gene Fusions in Over 34,000 Tumors

By Public Technologies
  • Caris Life Sciences on November 16, 2026, announced two studies already presented at the Association for Molecular Pathology’s 2026 annual meeting.
  • Patients with novel ALK or FGFR2 fusions had survival comparable to those with established fusions when receiving matched tyrosine kinase inhibitors.
  • Both groups survived longer than patients receiving treatments other than tyrosine kinase inhibitors.
  • A separate study identified rare PAK-family gene fusions in gynecologic serous cancers, potentially informing future targeted-therapy research.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk